Pazopanib

Catalog No.S3012 Synonyms: GW786034

Pazopanib Chemical Structure

Molecular Weight(MW): 437.52

Pazopanib is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM in cell-free assays, respectively.

Size Price Stock Quantity  
USD 70 In stock
USD 210 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

4 Customer Reviews

  • (a,b) Effect of Pazopanib on vascular network integrity. VMOs were exposed to drug from day 4 to 6. Data are normalized to day of first drug exposure and are shown as percentage of control. Error bars show mean ± s.d (n = 3) (p < 0.05 vs control).

    Sci Rep, 2016, 6:31589. Pazopanib purchased from Selleck.

    J Virol 2011 85(5), 2296-303. Pazopanib purchased from Selleck.

  • Three RCC cell lines treated with different concentrations of TKI and HDIL-2 and incubated for 48 h. Microscopic images show apoptotic materials 48 h following treatment (arrows show the apoptotic materials in the pazopanib-treated cells).

    Expert Opin Pharmacother 2014 15(11), 1489-99. Pazopanib purchased from Selleck.

    (B) The effects of AZD2014, BEZ235, lapatinib, LEE011, pazopanib on PI3K/AKT signaling in sarcoma PDC line were determined by immunoblotting analysis. Cells were treated with 1 μM of the indicated drugs for 72 h.

    Transl Oncol, 2016, 9(3):197-202. Pazopanib purchased from Selleck.

Purity & Quality Control

Choose Selective VEGFR Inhibitors

Biological Activity

Description Pazopanib is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM in cell-free assays, respectively.
Targets
VEGFR1 [1]
(Cell-free assay)
VEGFR2 [1]
(Cell-free assay)
VEGFR3 [1]
(Cell-free assay)
c-Kit [1]
(Cell-free assay)
PDGFR [1]
(Cell-free assay)
10 nM 30 nM 47 nM 74 nM 84 nM
In vitro

Pazopanib potently inhibits VEGF-induced phosphorylation of VEGFR2 in HUVEC cells with IC50 of 8 nM. [1] PPazopanib shows dose-dependent growth inhibition in all synovial sarcoma cell lines including SYO-1 and HS-SY-II cells. Proliferation of SYO-1 and HS-SY-II cells is inhibited even at 1 µg/mL of Pazopanib and is completely abolished at 5 µg/mL. Pazopanib induces G1 arrest, and thereby suppresses the growth of synovial sarcoma cells. Phosphorylation of Akts, GSK-3β, JNKs, p70 S6 Kinase, and mTOR is suppressed in Pazopanib-treated SYO-1 cells compared with that in the vehicle-treated cells. [2] Pazopanib between 20 m g/mL and 22.5 m g/mL shows an increasing reduction of RPE cell viability. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human EoL-1-cell cell M1fhW2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MnztTY5pcWKrdHnvckBw\iCqdX3hckBGd0xvMT3j[YxtKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIHnjOVA:Oi56OXWtNFUh|ryP M{PPOHNCVkeHUh?=
human AN3-CA cell MVnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MUfJcohq[mm2aX;uJI9nKGi3bXHuJGFPOy2FQTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGwMlA2KG6P MWTTRW5ITVJ?
human CGTH-W-1 cell Mn\US5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M33o[WlvcGmkaYTpc44hd2ZiaIXtZY4hS0eWSD3XMVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF01OC5yMTDuUS=> M1vCOXNCVkeHUh?=
human GDM-1 cell MXPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MV3Jcohq[mm2aX;uJI9nKGi3bXHuJGdFVS1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MUCzMlk6KG6P MYDTRW5ITVJ?
human A204 cell M1fTVmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M2PrZmlvcGmkaYTpc44hd2ZiaIXtZY4hSTJyNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGwPU4xPiCwTR?= MVXTRW5ITVJ?
human G-402 cell MoLRS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M4\qd2lvcGmkaYTpc44hd2ZiaIXtZY4hTy12MEKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21N|EvQDRibl2= MXHTRW5ITVJ?
human MFE-296 cell MXnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MV;Jcohq[mm2aX;uJI9nKGi3bXHuJG1HTS1{OU[gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlU6ODJ{IN88US=> NUHIXZhtW0GQR1XS
human NOS-1 cell MYHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NF3K[Y5KdmirYnn0bY9vKG:oIHj1cYFvKE6RUz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKGmlNUC9NE43PTl6NzFOwG0> M1;oPHNCVkeHUh?=
human KG-1 cell NH[3c3BIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NX;iWYVWUW6qaXLpeIlwdiCxZjDoeY1idiCNRz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE44OTd3NTFOwG0> MoLQV2FPT0WU
human HT55 cell MVLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NWnnTWEzUW6qaXLpeIlwdiCxZjDoeY1idiCKVEW1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE46QDd6MTFOwG0> NWHXdIloW0GQR1XS
human MG-63 cell MnrvS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MUHJcohq[mm2aX;uJI9nKGi3bXHuJG1INTZ|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT6wNFE1PiEQvF2= MV7TRW5ITVJ?
human CCF-STTG1 cell M{P2Nmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MlPuTY5pcWKrdHnvckBw\iCqdX3hckBES0ZvU2TUS|Eh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5Nige,:jDDJR|UxRTFwMES5PFEh|ryP NVK0cIpnW0GQR1XS
human RT-112 cell MVrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NHH6OGNKdmirYnn0bY9vKG:oIHj1cYFvKFKWLUGxNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvOTB|N{[g{txO NUjhXZgyW0GQR1XS
human MC-IXC cell MXzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MU\Jcohq[mm2aX;uJI9nKGi3bXHuJG1ENUm[QzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuNVE2OTJizszN MX3TRW5ITVJ?
human HUTU-80 cell NIjHT3dIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NWW3foplUW6qaXLpeIlwdiCxZjDoeY1idiCKVWTVMVgxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OS5{OEGwN{DPxE1? M{jRdnNCVkeHUh?=
human MV-4-11 cell NFLvT|VIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M2PXO2lvcGmkaYTpc44hd2ZiaIXtZY4hVVZvND2xNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvOzR3MEGg{txO MYjTRW5ITVJ?
human LCLC-103H cell MX7Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MXzJcohq[mm2aX;uJI9nKGi3bXHuJGxEVENvMUCzTEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6 MmnrV2FPT0WU
human G-401 cell NXu2XYtyT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MUfJcohq[mm2aX;uJI9nKGi3bXHuJGcuPDBzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT60OlQzOSEQvF2= NXTWbZJpW0GQR1XS
human A704 cell M4fMbWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NVj5VnhzUW6qaXLpeIlwdiCxZjDoeY1idiCDN{C0JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU43ODN{MzFOwG0> MnnjV2FPT0WU
human ESS-1 cell MVjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NHnWfWNKdmirYnn0bY9vKG:oIHj1cYFvKEWVUz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU43ODN7NjFOwG0> MV\TRW5ITVJ?
human HLE cell MojCS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? Mk[3TY5pcWKrdHnvckBw\iCqdX3hckBJVEViY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zLk[zPFA1KM7:TR?= MVPTRW5ITVJ?
human NY cell M2HY[2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NGrBU3BKdmirYnn0bY9vKG:oIHj1cYFvKE6\IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT64OFgzOSEQvF2= MofsV2FPT0WU
human A427 cell M1L5TWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Ml7jTY5pcWKrdHnvckBw\iCqdX3hckBCPDJ5IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT65PFA4PSEQvF2= M2PtZ3NCVkeHUh?=
human SK-N-DZ cell NGXmWnFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NEPsVoRKdmirYnn0bY9vKG:oIHj1cYFvKFONLV6tSHoh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zNjB{M{ixJO69VQ>? M33ucHNCVkeHUh?=
human J82 cell NWHRV2hwT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M{jRXWlvcGmkaYTpc44hd2ZiaIXtZY4hUjh{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mj6wOlA5QCEQvF2= NHf1S|NUSU6JRWK=
human GI-1 cell NV;rbZdCT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MVjJcohq[mm2aX;uJI9nKGi3bXHuJGdKNTFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{LkKyPVUyKM7:TR?= MkezV2FPT0WU
human NCI-H716 cell NXq1UHhmT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NIj6UnFKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3IO|E3KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oi5|MU[zN{DPxE1? NX3wfVE1W0GQR1XS
human SF126 cell NWi1RZpST3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M1jtN2lvcGmkaYTpc44hd2ZiaIXtZY4hW0ZzMk[gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlQ4PDV7IN88US=> MmPhV2FPT0WU
human H4 cell NH7nfndIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MnzBTY5pcWKrdHnvckBw\iCqdX3hckBJPCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTJwNUGyOlIh|ryP NGfi[4NUSU6JRWK=
human LB831-BLC cell MkDZS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NHn6W|dKdmirYnn0bY9vKG:oIHj1cYFvKEyEOEOxMWJNSyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTJwNUS1OlYh|ryP MlXkV2FPT0WU
human HCC1395 cell NFvp[4RIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M17XcWlvcGmkaYTpc44hd2ZiaIXtZY4hUEOFMUO5OUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvPThzNU[g{txO M1HJbnNCVkeHUh?=
human LK-2 cell NU\pW4w3T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MXjJcohq[mm2aX;uJI9nKGi3bXHuJGxMNTJiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{Lk[0OVY6KM7:TR?= MorEV2FPT0WU
human G-361 cell MYPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NW\xR4hzUW6qaXLpeIlwdiCxZjDoeY1idiCJLUO2NUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvODRyOEKg{txO M2q3e3NCVkeHUh?=
human NCI-H2342 cell NFr6eXdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NF3TcIZKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INlM1OiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LjDJR|UxRTNwMUOzNVYh|ryP NXyybZdsW0GQR1XS
human SK-LU-1 cell  MWHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NYnnU4dsUW6qaXLpeIlwdiCxZjDoeY1idiCVSz3MWU0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oy5zOEe2O{DPxE1? MmXXV2FPT0WU
human IGROV-1 cell  NW[4bohJT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MlPpTY5pcWKrdHnvckBw\iCqdX3hckBKT1KRVj2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{4zPDdzMzFOwG0> NXjjdZg5W0GQR1XS
human EB2 cell NVzDeIszT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NFS4XpVKdmirYnn0bY9vKG:oIHj1cYFvKEWEMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOuNlgyPjhizszN Mmj0V2FPT0WU
human CAL-54 cell MoOwS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MmniTY5pcWKrdHnvckBw\iCqdX3hckBESUxvNUSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlI5OzZ5IN88US=> MojOV2FPT0WU
human LB1047-RCC cell MVLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NXLDO3BzUW6qaXLpeIlwdiCxZjDoeY1idiCRQ2XCMW0h[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{NjN|MUO2PEDPxE1? M{DxRnNCVkeHUh?=
Daudi cell MWjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NVP4[Y8{UW6qaXLpeIlwdiCxZjDoeY1idiCOQkGwOFcuWkOFIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mz61N|E3PCEQvF2= NVnSUoc{W0GQR1XS
human Daudi cell MYDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M1PCSWlvcGmkaYTpc44hd2ZiaIXtZY4hTGG3ZHmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlY3OjF7IN88US=> MUDTRW5ITVJ?
human A172 cell NHntSpFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MoGxTY5pcWKrdHnvckBw\iCqdX3hckBCOTd{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mz63N|c6KM7:TR?= NFfsfHFUSU6JRWK=
human KGN cell MYfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NGXzNYhKdmirYnn0bY9vKG:oIHj1cYFvKEuJTjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUSuNFY4ODlizszN M1;FV3NCVkeHUh?=
human SNG-M cell Mm\OS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NIDQXoJKdmirYnn0bY9vKG:oIHj1cYFvKFOQRz3NJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE4xQDZ4OTFOwG0> M2Cy[XNCVkeHUh?=
human SW1710 cell MW\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M1LvXmlvcGmkaYTpc44hd2ZiaIXtZY4hW1dzN{GwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE41PzNzODFOwG0> NGTGeHNUSU6JRWK=
human HT29 cells MYjQdo9tcW[ncnH0bY9vKGG|c3H5 NYfkVpp3SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIWFI6KGOnbHzzJIlvKHOncoXtJINwdnSjaX7pcochdWWmaYXt M2e0blE5PjJyM{iy
human A375P cells MU\Qdo9tcW[ncnH0bY9vKGG|c3H5 NUP5cXhVSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDBN|c2WCClZXzsd{BqdiC|ZYL1cUBkd262YXnubY5oKG2nZHn1cS=> M3PpNlE5PjJyM{iy
human HN5 cells M1TvPHBzd2yrZnXyZZRqd25iYYPzZZk> MX;BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiQNTDj[YxteyCrbjDz[ZJ2dSClb370ZYlvcW6pIH3l[Il2dQ>? NIHVSHAyQDZ{MEO4Ni=>
HUVEC M4HMRmZ2dmO2aX;uJIF{e2G7 M3vZelEh|ryP NUTocHJCPiCq MkDaRY51cWGwZ3nv[4VvcWNiYXP0bZZqfHliaX6gTHVXTUNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iC2dXLlJIZwem2jdHnvckBifCByLkGgeW0h[W[2ZYKgOkBpenNiYomgUYF1emmpZXygZZN{[Xl? M2XQbFI1ODN4MESy
human Daoy cell M{T3fWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MniwTY5pcWKrdHnvckBw\iCqdX3hckBF[W:7IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;ND63O|k1QSEQvF2= MlPSV2FPT0WU
human DMS-273 cell M4\Mc2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NE\T[3lKdmirYnn0bY9vKG:oIHj1cYFvKESPUz2yO|Mh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF01Njl4MkCyJO69VQ>? MVvTRW5ITVJ?
human KU812 cell NHfnTohIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MmC5TY5pcWKrdHnvckBw\iCqdX3hckBMXThzMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUWuN|c5OTJizszN M2e1XXNCVkeHUh?=
human NCI-H727 cell NYDyUpZUT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NYfVUoIzUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFczPyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTVwNEC5NFEh|ryP NGH5RplUSU6JRWK=
human P30-OHK cell MUnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M1f4b2lvcGmkaYTpc44hd2ZiaIXtZY4hWDNyLV;IT{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvPDZ7NDFOwG0> MlPoV2FPT0WU
human MIA-PaCa-2 cell MkjFS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M13MPWlvcGmkaYTpc44hd2ZiaIXtZY4hVUmDLWDhR4EuOiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTVwNkC0OlYh|ryP NFm3T2hUSU6JRWK=
human TT cell MorRS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MmfITY5pcWKrdHnvckBw\iCqdX3hckBVXCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTVwNk[yOEDPxE1? M2TwU3NCVkeHUh?=
human DK-MG cell NFHOdHVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NUnHZ2JPUW6qaXLpeIlwdiCxZjDoeY1idiCGSz3NS{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvPzJyMkig{rxu NYnu[41GW0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo The mice treated with 30 mg/kg or 100 mg/kg Pazopanib reveals a significant decrease in tumor burden compared with the mice treated with vehicle or 10 mg/kg Pazopanib. Treatment with Pazopanib is well-tolerated and there is no significant difference in the body weight among the mice in each group. [2]

Protocol

Animal Research:

[2]

+ Expand
  • Animal Models: Immunodeficient mice bearing SYO-1 cells
  • Formulation: --
  • Dosages: 0 mg/kg, 10 mg/kg, 30 mg/kg, or 100 mg/kg
  • Administration: Oral administration
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 87 mg/mL warmed (198.84 mM)
Water Insoluble
Ethanol Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 437.52
Formula

C21H23N7O2S

CAS No. 444731-52-6
Storage powder
Synonyms GW786034

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02300545 Recruiting Sarcoma, Soft Tissue|Soft Tissue Sarcoma Washington University School of Medicine April 8, 2015 Phase 2
NCT00674024 Completed Neoplasms|Lymphoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 7, 2008 Phase 1
NCT01716416 Recruiting Squamous Cell Carcinoma of the Head and Neck Washington University School of Medicine May 31, 2013 Phase 1
NCT01462630 Recruiting Adult Angiosarcoma|Recurrent Adult Soft Tissue Sarcoma|Stage III Adult Soft Tissue Sarcoma|Stage IV Adult Soft Tissue Sarcoma Fox Chase Cancer Center|National Cancer Institute (NCI) November 3, 2011 Phase 2
NCT01468922 Completed Sarcoma|Stomach Neoplasms|Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 24, 2011 Phase 1
NCT02342600 Not yet recruiting Gastrointestinal Stromal Tumors Sarcoma Alliance for Research through Collaboration|Novartis January 2017 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

VEGFR Signaling Pathway Map

Related VEGFR Products

Tags: buy Pazopanib | Pazopanib supplier | purchase Pazopanib | Pazopanib cost | Pazopanib manufacturer | order Pazopanib | Pazopanib distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID